A carregar...
Switching from infliximab to biosimilar in inflammatory bowel disease: overview of the literature and perspective
BACKGROUND: Biological therapy has revolutionized the treatment of inflammatory bowel disease (IBD). After the expiration of patents for biological innovator products, development of biosimilars increased. CT-P13 was the first biosimilar approved for the same indications as the reference product; ho...
Na minha lista:
| Publicado no: | Therap Adv Gastroenterol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6469269/ https://ncbi.nlm.nih.gov/pubmed/31019554 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756284819842748 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|